Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · IEX Real-Time Price · USD
4.000
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
3.910
-0.090 (-2.25%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.
The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc.
Country | United States |
Founded | 2006 |
IPO Date | Oct 3, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Dr. Oren Gilad Ph.D. |
Contact Details
Address: 3805 Old Easton Road Doylestown, Pennsylvania 18902 United States | |
Phone | 617-463-9385 |
Website | atrinpharma.com |
Stock Details
Ticker Symbol | APRE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $15.00 |
CIK Code | 0001781983 |
CUSIP Number | 03836J102 |
ISIN Number | US03836J2015 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Oren Gilad Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
John P. Hamill CPA | Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
Dr. Dansu Li Ph.D. | Head of Technology |
Dr. Lars B. Abrahmsen Ph.D. | Senior Vice President and Chief Scientific Officer |
Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
Andrea Epstein | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 20, 2024 | 8-K | Current Report |
Jun 17, 2024 | 8-K | Current Report |
May 14, 2024 | 8-K | Current Report |
May 14, 2024 | 10-Q | Quarterly Report |
Apr 30, 2024 | 424B3 | Prospectus |
Apr 29, 2024 | EFFECT | Notice of Effectiveness |
Apr 25, 2024 | ARS | Filing |
Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
Apr 10, 2024 | 8-K | Current Report |